European Journal of Cancer Supplements This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

P81
Publication date: November 2015 Source:European Journal of Cancer Supplements, Volume 13, Issue 1 Author(s): E. Batorov, M. Tikhonova, I. Kryuchkova, V. Sergeevicheva, D. Batorova, S. Sizikova, G. Ushakova, A. Gilevich, A. Ostanin, E. Chernykh Numerous studies have shown that high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) led to a profound and long-lasting state of immunodeficiency characterized by persisting low levels of T cells in hemoblastosis patients. Well-timed T-cell reconstitution is crucial for early restoration of anti-infectious and anti- tumor immu...
Source: European Journal of Cancer Supplements - November 24, 2015 Category: Cancer & Oncology Source Type: research

T86
Publication date: November 2015 Source:European Journal of Cancer Supplements, Volume 13, Issue 1 Author(s): N. Barlev, O. Fedorova, L. Lezina, S. Piletsky Discovery of new pharmacologically active small molecules is an important and rapidly expanding area of modern molecular pharmacology. Given a limited number of proteins that are druggable, it is important to identify as many chemical effectors as possible to define the best regimen of anti-cancer therapy in each particular case. An E3 ubiquitin ligase, Mdm2, which mediates ubiquitin-dependent degradation of the critical tumor suppressor p53, is a promising ...
Source: European Journal of Cancer Supplements - November 24, 2015 Category: Cancer & Oncology Source Type: research

T125
Publication date: November 2015 Source:European Journal of Cancer Supplements, Volume 13, Issue 1 Author(s): O. Bajenova, I. Evsyukov, S. O’Brien Tumor markers play an important role in the identification of human malignancies. It has been shown that the carcinoembryonic antigen (CEA, CEACAM5) is a promoter of metastasis in epithelial cancers that is widely used as a clinical marker. The aim of this study is to elucidate the network of genes that are involved in the CEA-induced liver metastasis. Previously, we have shown that CEA is accumulated in the lungs and livers of rats by interacting with their macrophag...
Source: European Journal of Cancer Supplements - November 24, 2015 Category: Cancer & Oncology Source Type: research

P6
Conclusion These data suggest that the distribution pattern of ERα expression, EGFR expression and ESR1 2014G>A genetic variation could be useful additional prognostic markers for hormone receptor-positive breast cancer patients treated with adjuvant tamoxifen. (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - November 24, 2015 Category: Cancer & Oncology Source Type: research

T117
Publication date: November 2015 Source:European Journal of Cancer Supplements, Volume 13, Issue 1 Author(s): A. Alexandrova, A. Chikina During cancer development, tumor cells gain the ability to invade and metastasize. Individual cells use alternative migration modes based on different cellular mechanisms. One of them is mesenchymal motility mode which is driven by leading edge protrusion in the form of filopodia or/and lamellipodia based on Arp2/3 dependent actin polymerization. Mesenchymal motility depends on formation of cell-substrate adhesions, activity of matrix metalloproteases (MMPs) and on activity of smal...
Source: European Journal of Cancer Supplements - November 24, 2015 Category: Cancer & Oncology Source Type: research

P28
Publication date: November 2015 Source:European Journal of Cancer Supplements, Volume 13, Issue 1 Author(s): M. Aksenenko, T. Ruksha Melanoma is one of the aggressive cancer types. Mutations that lock the BRAF protein in an active state may cause excessive signaling in the pathway, leading to uncontrolled cell growth and survival. Primarily among the BRAF mutations observed in melanoma, over 90% are supposed to be at codon 600, resulting in substitution of glutamic acid for valine, V600E (T>A transversion) located in exon 15, BRAFV600E. Of particular interest is BRAF negative melanoma. This type of melanoma ...
Source: European Journal of Cancer Supplements - November 24, 2015 Category: Cancer & Oncology Source Type: research

Letter of Welcome
Publication date: November 2015 Source:European Journal of Cancer Supplements, Volume 13, Issue 1 (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - November 24, 2015 Category: Cancer & Oncology Source Type: research

Title page 2
Publication date: November 2015 Source:European Journal of Cancer Supplements, Volume 13, Issue 1 (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - November 24, 2015 Category: Cancer & Oncology Source Type: research

Title page 1
Publication date: November 2015 Source:European Journal of Cancer Supplements, Volume 13, Issue 1 (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - November 24, 2015 Category: Cancer & Oncology Source Type: research

TEMPORARY REMOVAL: Real-life experience using trabectedin plus pegylated liposomal doxorubicin combination to treat patients with relapsed ovarian cancer
Publication date: December 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 2 Author(s): Saad Tahir The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - January 20, 2015 Category: Cancer & Oncology Source Type: research

TEMPORARY REMOVAL: Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
Publication date: December 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 2 Author(s): Christina Fotopoulou The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - January 20, 2015 Category: Cancer & Oncology Source Type: research

TEMPORARY REMOVAL: Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient
Publication date: December 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 2 Author(s): Nicoletta Colombo The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - January 20, 2015 Category: Cancer & Oncology Source Type: research

TEMPORARY REMOVAL: Introduction to managing patients with recurrent ovarian cancer
Publication date: December 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 2 Author(s): Hani Gabra The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - January 20, 2015 Category: Cancer & Oncology Source Type: research

TEMPORARY REMOVAL: Foreword
Publication date: December 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 2 Author(s): Hani Gabra The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - January 20, 2015 Category: Cancer & Oncology Source Type: research

Real-life experience using trabectedin plus pegylated liposomal doxorubicin combination to treat patients with relapsed ovarian cancer
Publication date: December 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 2 Author(s): Saad Tahir The goal of recurrent ovarian cancer (ROC) treatment is no longer just palliation, but prolonging survival. This is usually through administering a new line of chemotherapy at each relapse. A novel treatment sequencing strategy to achieve this is through the intercalation of an effective non-platinum alternative, in between platinum-based therapies. Trabectedin in combination with pegylated liposomal doxorubicin (PLD) has been fully available privately in the UK since 2009 for treating patients with ...
Source: European Journal of Cancer Supplements - January 15, 2015 Category: Cancer & Oncology Source Type: research